The global circulating tumor cell market was valued at $1.12 billion in 2021, and is projected to reach $5.88 billion by 2031, registering a CAGR of 18.0%.
Circulating cancer cells are the cells formed due to the process of cell metastasis, which is the most lethal state of cancer. These cells are generally sloughed off from the primary tumor and get circulated into the blood circulation. These circulating tumor cells may undergo intravasation, survival, and extravasation from the bloodstream, and get attached to metastatic site to form colonies and lead to cancer metastasis.
Though, CTCs originate from the primary tumor, they are different from primary tumor cells, having epithelial-mesenchymal transition properties, which break them free from the primary tumor. However, CTCs are very rare in nature and hence, are challenging to detect in massive blood cells. They can be further detected using molecular markers that are unique for particular form of cancer and are used for CTC detection. However, epithelial cell adhesion molecule is the most commonly employed molecular marker for the detection of CTCs.
Moreover, detection of CTC is a complex process, which involves the use of advanced technologies for the detection and enumeration of circulating tumor cells. As circulating tumor cells assists in the early detection and real-time monitoring of lung, breast, digestive tract, and prostate cancer, there is a rise in the demand for these techniques and technologies, which are used for CTC detection. In addition, rise in the use of CTC in preclinical cancer medication research and patient metastasis screening boosts the market growth.
Furthermore, increase in prevalence of cancer is one of the major factors contributing to the market growth. For instance, according to an article by National Cancer Institute (NCI) in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S. and 606,520 people died from the cancer and related conditions. In addition, presence of circulating tumor cells in the patient proves to be an indication for cancer. Thus, it can be used for an early detection of cancer, thereby assisting the healthcare provider in deciding the treatment regime.
Furthermore, advancements in the field of diagnosis and treatments of cancer is driving the market growth. Several advancements have been done by researchers and manufacturers in the healthcare sector, which makes the diagnosis and treatment procedure more efficient and accurate. There are also huge advancements in the field of circulating tumor cells.
For instance, the development of Parsortix method, Cell search system, Epic Sciences method, and Maintrac system has made the detection of circulating tumor cells easier and more efficient. Thus, such advances in the healthcare sector along with major developments in circulating tumor cell detection, augments the growth of the circulating tumor cell market.
The circulating tumor cell market is segmented on the basis of technology, application, end user, and region. By technology, the market is categorized into CTC detection and enrichment methods, CTC direct detection methods, and CTC analysis. The CTC detection and enrichment methods segment is further segmented into immunocapture, size-based separation, density-based separation, combined methods, and others. On the other hand, the CTC direct detection methods segment is further divided into surface-enhanced Raman scattering (SERS), microscopy, and others.
On the basis of application, the market is segmented into clinical and research. On the basis end user, it is segmented into hospitals and clinics, diagnostic centers, and others. The others segment includes, research centers and academic research institutes. Region-wise, it is studied across North America, Europe, Asia-Pacific, and LAMEA. Some of the major companies that operate in the global circulating tumor cell market are Biocept, Inc., Greiner AG (Greiner Bio One International GmbH), Menarini Group (Menarini Silicon Biosystems), Miltenyi Biotec, Precision Medicine Group (Precision for medicine), Qiagen N.V., SRI International, Stemcell Technologies Inc., Sysmex Corporation, and Thermo Fisher Scientific.
Circulating cancer cells are the cells formed due to the process of cell metastasis, which is the most lethal state of cancer. These cells are generally sloughed off from the primary tumor and get circulated into the blood circulation. These circulating tumor cells may undergo intravasation, survival, and extravasation from the bloodstream, and get attached to metastatic site to form colonies and lead to cancer metastasis.
Though, CTCs originate from the primary tumor, they are different from primary tumor cells, having epithelial-mesenchymal transition properties, which break them free from the primary tumor. However, CTCs are very rare in nature and hence, are challenging to detect in massive blood cells. They can be further detected using molecular markers that are unique for particular form of cancer and are used for CTC detection. However, epithelial cell adhesion molecule is the most commonly employed molecular marker for the detection of CTCs.
Moreover, detection of CTC is a complex process, which involves the use of advanced technologies for the detection and enumeration of circulating tumor cells. As circulating tumor cells assists in the early detection and real-time monitoring of lung, breast, digestive tract, and prostate cancer, there is a rise in the demand for these techniques and technologies, which are used for CTC detection. In addition, rise in the use of CTC in preclinical cancer medication research and patient metastasis screening boosts the market growth.
Furthermore, increase in prevalence of cancer is one of the major factors contributing to the market growth. For instance, according to an article by National Cancer Institute (NCI) in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S. and 606,520 people died from the cancer and related conditions. In addition, presence of circulating tumor cells in the patient proves to be an indication for cancer. Thus, it can be used for an early detection of cancer, thereby assisting the healthcare provider in deciding the treatment regime.
Furthermore, advancements in the field of diagnosis and treatments of cancer is driving the market growth. Several advancements have been done by researchers and manufacturers in the healthcare sector, which makes the diagnosis and treatment procedure more efficient and accurate. There are also huge advancements in the field of circulating tumor cells.
For instance, the development of Parsortix method, Cell search system, Epic Sciences method, and Maintrac system has made the detection of circulating tumor cells easier and more efficient. Thus, such advances in the healthcare sector along with major developments in circulating tumor cell detection, augments the growth of the circulating tumor cell market.
The circulating tumor cell market is segmented on the basis of technology, application, end user, and region. By technology, the market is categorized into CTC detection and enrichment methods, CTC direct detection methods, and CTC analysis. The CTC detection and enrichment methods segment is further segmented into immunocapture, size-based separation, density-based separation, combined methods, and others. On the other hand, the CTC direct detection methods segment is further divided into surface-enhanced Raman scattering (SERS), microscopy, and others.
On the basis of application, the market is segmented into clinical and research. On the basis end user, it is segmented into hospitals and clinics, diagnostic centers, and others. The others segment includes, research centers and academic research institutes. Region-wise, it is studied across North America, Europe, Asia-Pacific, and LAMEA. Some of the major companies that operate in the global circulating tumor cell market are Biocept, Inc., Greiner AG (Greiner Bio One International GmbH), Menarini Group (Menarini Silicon Biosystems), Miltenyi Biotec, Precision Medicine Group (Precision for medicine), Qiagen N.V., SRI International, Stemcell Technologies Inc., Sysmex Corporation, and Thermo Fisher Scientific.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the circulating tumor cell market analysis from 2021 to 2031 to identify the prevailing circulating tumor cell market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the circulating tumor cell market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global circulating tumor cell market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update* (with the purchase of an enterprise license)
- 5 additional Company Profiles, pre- or post-purchase, as a free update.
- Free Updated Version (once released) with the purchase of an enterprise user license.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Market share analysis of players by products/segments
- New Product Development/ Product Matrix of Key Players
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Average Selling Price Analysis / Price Point Analysis
- Expanded list for Company Profiles
- Historic market data
Key Market Segments
By Product
- Kits Reagents
- Blood Collection Tubes
- Devices
By Technology
- CTC Detection Enrichment Methods
- CTC Direct Detection
- CTC Analysis
By Application
- Research, Clinical
- Drug/Therapy Development
By Specimen
- Blood
- Bone Marrow
- Other Body Fluids
By End User
- Hospital and Clinics
- Diagnostic Centers
- Research and Academic Institutes
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Qiagen NV.
- Bio-Techne Corporation
- Precision for Medicine, Inc.
- AVIVA Biosciences
- BioCEP Ltd
- Fluxion Biosciences, Inc
- Greiner Bio-One International GmbH
- Ikonisys, Inc
- Miltenyi Biotec GmbH.
- IVDiagnostics, Inc
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY
CHAPTER 5: CIRCULATING TUMOR CELL MARKET, BY APPLICATION
CHAPTER 6: CIRCULATING TUMOR CELL MARKET, BY END USERS
CHAPTER 7: CIRCULATING TUMOR CELL MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Qiagen NV.
- Bio-Techne Corporation
- Precision for Medicine, Inc.
- AVIVA Biosciences
- BioCEP Ltd
- Fluxion Biosciences, Inc
- Greiner Bio-One International GmbH
- Ikonisys, Inc
- Miltenyi Biotec GmbH.
- IVDiagnostics, Inc
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 280 |
| Published | September 2024 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 1.12 billion |
| Forecasted Market Value ( USD | $ 5.88 billion |
| Compound Annual Growth Rate | 18.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
